Nonalcoholic fatty liver disease in lean subjects: is it all metabolic-associated fatty liver disease?

Abstract

The epidemiology of nonalcoholic fatty liver disease goes hand-in-hand with the obesity pandemic. The pathogenesis of fatty liver has shifted from an hepatocentric view to an adipocentric view, in which the overloaded adipose tissue spills out lipids that spread to ectopic tissues and organs such as the liver, elicits inflammation, and changes its adipokines profile promoting insulin resistance and the metabolic syndrome. Up to 40% of nonalcoholic fatty liver disease (NAFLD) patients are not obese and up to 20% are actually lean. Furthermore roughly 10% of lean subjects have NAFLD. In fact, adiposopathy can occur in patients with normal weight, and it is associated with expansion of metabolically active visceral fat and a qualitatively different adipose tissue that becomes overwhelmed after challenged by a mildly positive energy balance. This defines the concept of personal fat threshold that when exceeded results in metabolic dysfunction. Overweight/obese persons have higher probability of exceeding that threshold, explaining why adiposopathy/metabolic syndrome/NAFLD is more frequent in the obese. In this article, the epidemiology, pathogenesis, and management of patients with lean NAFLD are reviewed with an emphasis on reconciling the concepts of NAFLD in its relationship with adiposity and of NAFLD in lean individuals.

Keywords

Lean nonalcoholic fatty liver disease / metabolically obese normal weight / visceral adipose tissue

References

[1] Younossi Z,Marietti M.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention..Nat Rev Gastroenterol Hepatol2018;15:11-20

[2] Best CH.Liver damage produced by feeding alcohol or sugar and its prevention by choline..Br Med J1949;2:1002-6pl PMCID:PMC2051633

[3] Zelman S.The liver in obesity..AMA Arch Intern Med1952;90:141-56

[4] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease..Mayo Clin Proc1980;55:434-8

[5] Angulo P.Nonalcoholic fatty liver disease..N Engl J Med2002;346:1221-31

[6] Clark JM,Diehl AM.Nonalcoholic fatty liver disease..Gastroenterology2002;122:1649-57

[7] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement..J Hepatol2020;73:202-9

[8] Machado MV.Management of fatty liver disease with the metabolic syndrome..Expert Rev Gastroenterol Hepatol2014;8:487-500

[9] Younossi ZM,Younossi Y.Epidemiology of chronic liver diseases in the USA in the past three decades..Gut2020;69:564-8

[10] Chen CH,Yang JC.Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults..J Clin Gastroenterol2006;40:745-52

[11] Younossi ZM,Negro F.Nonalcoholic fatty liver disease in lean individuals in the United States..Medicine (Baltimore)2012;91:319-27

[12] Young S,Provenza J.Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis..Hepatol Commun2020;4:953-72 PMCID:PMC7327210

[13] Ye Q,Yeo YH.Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis..Lancet Gastroenterol Hepatol2020;5:739-52

[14] Das K,Mukherjee PS.Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease..Hepatology2010;51:1593-602

[15] Machado MV.Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal..J Hepatol2013;58:1007-19

[16] Weir CB.BMI classification percentile and cut off points. StatPearls.2020;Treasure Island (FL)StatPearls Publishing

[17] Consultation WHOE.Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies..Lancet2004;363:157-63

[18] Shi Y,Sun Y.The prevalence of lean/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis..J Clin Gastroenterol2020;54:378-87

[19] Bellentani S,Masutti F.Prevalence of and risk factors for hepatic steatosis in Northern Italy..Ann Intern Med2000;132:112-7

[20] Feng RN,Wang C.Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population..World J Gastroenterol2014;20:17932-40 PMCID:PMC4273143

[21] Nishioji K,Kamaguchi M.Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012..J Gastroenterol2015;50:95-108

[22] Wei JL,Loong TC.Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy..Am J Gastroenterol2015;110:1306-14quiz 15

[23] Kim SS,Kim HJ.Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects..Dig Liver Dis2018;50:370-7

[24] Sinn DH,Cho SJ.Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study..Eur J Endocrinol2019;181:185-92

[25] Browning JD,Dobbins R.Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity..Hepatology2004;40:1387-95

[26] Alberti KG,Shaw J.The metabolic syndrome--a new worldwide definition..Lancet2005;366:1059-62

[27] Sookoian S.Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients..Aliment Pharmacol Ther2017;46:85-95

[28] Feldman A,Felder TK.Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver..Am J Gastroenterol2017;112:102-10

[29] Margariti E,Manolakopoulos S.Non-alcoholic fatty liver disease may develop in individuals with normal body mass index..Ann Gastroenterol2012;25:45-51 PMCID:PMC3959339

[30] Kumar R,Sharma MK.Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease?.Indian J Endocrinol Metab2013;17:665-71 PMCID:PMC3743367

[31] Kwon YM,Hwang SS,Kwon H.Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults..Am J Gastroenterol2012;107:1852-8

[32] Xu C,Ma H,Miao M.Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study..Am J Gastroenterol2013;108:1299-304

[33] Kim NH,Kim YJ.Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects..Liver Int2014;34:604-11

[34] Wong VW,Yeung DK.Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy..J Hepatol2015;62:182-9

[35] Niriella MA,Pathmeswaran A.Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka..Hepatol Int2019;13:314-22

[36] Li L,Yan HY,Zhao SH.Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies..Obes Rev2016;17:510-9

[37] Kumar R.Non-alcoholic fatty liver disease in lean subjects: characteristics and implications..J Clin Transl Hepatol2017;5:216-23 PMCID:PMC5606968

[38] Bernhardt P,Schmidberger J,Gruener B.Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis..BMC Res Notes2018;11:101 PMCID:PMC5801753

[39] Younes R.NASH in Lean Individuals..Semin Liver Dis2019;39:86-95

[40] Trepo E.Update on NAFLD genetics: from new variants to the clinic..J Hepatol2020;72:1196-209

[41] Adams LC,Bressem K,Hamm B.Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: a case-control study..PLoS One2018;13:e0206450 PMCID:PMC6241122

[42] Buchman AL,Spilker B.The differentiation of intestinal-failure-associated liver disease from nonalcoholic fatty liver and nonalcoholic steatohepatitis..Semin Liver Dis2017;37:33-44

[43] Duarte SMB,Miele L.Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study..Nutr Metab Cardiovasc Dis2018;28:369-84

[44] Yildiz Y.Inborn errors of metabolism in the differential diagnosis of fatty liver disease..Turk J Gastroenterol2020;31:3-16 PMCID:PMC7075690

[45] Machado MV.Pathogenesis of nonalcoholic steatohepatitis..Gastroenterology2016;150:1769-77 PMCID:PMC4887389

[46] Ruderman NB,Berchtold P.The “metabolically-obese” normal-weight individual..Am J Clin Nutr1981;34:1617-21

[47] Stefan N,Haring HU.Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans..Cell Metab2017;26:292-300

[48] Kramer CK,Retnakaran R.Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis..Ann Intern Med2013;159:758-69

[49] Rothman KJ.BMI-related errors in the measurement of obesity..Int J Obes (Lond).2008;32 Suppl 3:S56-9

[50] Gujral UP,Mongraw-Chaffin M.Cardiometabolic abnormalities among normal-weight persons from five racial/Ethnic Groups in the United States: a cross-sectional analysis of two cohort studies..Ann Intern Med2017;166:628-36 PMCID:PMC5545925

[51] Wang B,Luo X.Prevalence of metabolically healthy obese and metabolically obese but normal weight in adults worldwide: a meta-analysis..Horm Metab Res2015;47:839-45

[52] Taylor R.Normal weight individuals who develop type 2 diabetes: the personal fat threshold..Clin Sci (Lond)2015;128:405-10

[53] Du T,Zhang J.Lipid accumulation product and visceral adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype..Acta Diabetol2015;52:855-63

[54] Neeland IJ,Despres JP.Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement..Lancet Diabetes Endocrinol2019;7:715-25

[55] Zierath JR,Thorne A.Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway..Diabetologia1998;41:1343-54

[56] Nielsen S,Johnson CM,Jensen MD.Splanchnic lipolysis in human obesity..J Clin Invest2004;113:1582-8 PMCID:PMC419492

[57] Feng R,Li C.Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case - control study..Lipids Health Dis2017;16:165 PMCID:PMC5584533

[58] Tchernof A.Pathophysiology of human visceral obesity: an update..Physiol Rev2013;93:359-404

[59] Wensveen FM,Sestan M,Polic B.The “Big Bang” in obese fat: events initiating obesity-induced adipose tissue inflammation..Eur J Immunol2015;45:2446-56

[60] Hamaguchi M,Itoh Y.The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation..Am J Gastroenterol2007;102:2708-15

[61] Park BJ,Kim DH.Visceral adipose tissue area is an independent risk factor for hepatic steatosis..J Gastroenterol Hepatol2008;23:900-7

[62] Chung GE,Kwark MS.Visceral adipose tissue area as an independent risk factor for elevated liver enzyme in nonalcoholic fatty liver disease..Medicine (Baltimore)2015;94:e573 PMCID:PMC4553965

[63] Yu SJ,Kim D.Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease..Medicine (Baltimore)2015;94:e2159 PMCID:PMC4674200

[64] Choe EY,Choi YJ.Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes..J Gastroenterol Hepatol2018;33:1082-91

[65] Kure T,Imamura Y.Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: a cross-sectional study..Medicine (Baltimore)2019;98:e17879 PMCID:PMC6867727

[66] Kim D,Kwak MS.Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease..Clin Gastroenterol Hepatol2016;14:132-8.e4

[67] Kim HJ,Lee KE.Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults..Arch Intern Med2004;164:2169-75

[68] Yasutake K,Shima Y.Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol..Scand J Gastroenterol2009;44:471-7

[69] Shida T,Suzuki H.Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan..Hepatol Res2020;

[70] Nakamuta M,Higuchi N.The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease..Int J Mol Med2008;22:663-7

[71] Karpe F.Biology of upper-body and lower-body adipose tissue--link to whole-body phenotypes..Nat Rev Endocrinol2015;11:90-100

[72] Sahakyan KR,Rodriguez-Escudero JP.Normal-weight central obesity: implications for total and cardiovascular mortality..Ann Intern Med2015;163:827-35 PMCID:PMC4995595

[73] Snijder MB,Visser M,Seidell JC.Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study..Int J Obes Relat Metab Disord2004;28:402-9

[74] Yusuf S,Ounpuu S.Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study..Lancet2005;366:1640-9

[75] Tchoukalova YD,Tchkonia T,Kirkland JL.Regional differences in cellular mechanisms of adipose tissue gain with overfeeding..Proc Natl Acad Sci U S A2010;107:18226-31 PMCID:PMC2964201

[76] Pinnick KE,Manolopoulos KN.Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications..Diabetes2014;63:3785-97

[77] Lotta LA,Day FR.Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance..Nat Genet2017;49:17-26 PMCID:PMC5774584

[78] Zheng RD,Chen JN,Chen J.Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalcoholic fatty liver disease..Gastroenterol Res Pract2012;2012:362147 PMCID:PMC3369513

[79] Lee YH,Song K.Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008-2011)..Hepatology2016;63:776-86

[80] Hong HC,Choi HY.Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean sarcopenic obesity study..Hepatology2014;59:1772-8

[81] Issa D,Tsien C.Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis..Hepatology2014;60:428-9 PMCID:PMC4539562

[82] Koo BK,Joo SK.Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis..J Hepatol2017;66:123-31

[83] Petta S,Di Marco V.Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease..Aliment Pharmacol Ther2017;45:510-8

[84] Yu R,Liu L.Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis..BMC Gastroenterol2018;18:51 PMCID:PMC5907709

[85] Cai C,Chen Y,Yu C.Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis..Hepatol Int2020;14:115-26 PMCID:PMC6994447

[86] Tobari M,Taniai M.Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign..J Gastroenterol Hepatol2019;34:1404-10

[87] Machado MV,Castro RE.Liver and muscle in morbid obesity: the interplay of fatty liver and insulin resistance..PLoS One2012;7:e31738 PMCID:PMC3281005

[88] Bhanji RA,Allen AM,Watt KD.Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis..Hepatology2017;66:2055-65

[89] Kalyani RR,Ferrucci L.Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases..Lancet Diabetes Endocrinol2014;2:819-29 PMCID:PMC4156923

[90] Hernandez-Alvarez MI,Burns N.Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1{alpha}/Mitofusin-2 regulatory pathway in response to physical activity..Diabetes Care2010;33:645-51 PMCID:PMC2827524

[91] Phillips T.Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction..FASEB J2005;19:668-70

[92] Rubio-Ruiz ME,Perez-Torres I.Mechanisms underlying metabolic syndrome-related sarcopenia and possible therapeutic measures..Int J Mol Sci2019;20:647 PMCID:PMC6387003

[93] Defronzo RA.Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus..Diabetes2009;58:773-95 PMCID:PMC2661582

[94] Kim TN,Yoo HJ.Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study..Int J Obes (Lond)2009;33:885-92

[95] Bostrom P,Jedrychowski MP.A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis..Nature2012;481:463-8 PMCID:PMC3522098

[96] Zhang HJ,Ma ZM.Irisin is inversely associated with intrahepatic triglyceride contents in obese adults..J Hepatol2013;59:557-62

[97] Huh JY.The role of exercise-induced myokines in regulating metabolism..Arch Pharm Res2018;41:14-29

[98] Han HQ,Mitch WE.Myostatin/activin pathway antagonism: molecular basis and therapeutic potential..Int J Biochem Cell Biol2013;45:2333-47

[99] Li F,Duan Y,Tang Y.Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose tissue..Cytokine Growth Factor Rev2017;33:73-82

[100] Konopka AR,Suer MK.Relationship between intermuscular adipose tissue infiltration and myostatin before and after aerobic exercise training..Am J Physiol Regul Integr Comp Physiol2018;315:R461-8 PMCID:PMC6734080

[101] Delogu W,Provenzano A.Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation..Dig Liver Dis2019;51:1400-8

[102] Garcia PS,Kambadur R,Csete M.Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting..Anesth Analg2010;111:707-9

[103] Nishikawa H,Ishii A.Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis..J Cachexia Sarcopenia Muscle2017;8:915-25 PMCID:PMC5700437

[104] Shida T,Oh S,Shoda J.Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease..Diabetes Metab Syndr Obes2019;12:495-503 PMCID:PMC6489648

[105] Romeo S,Xing C.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease..Nat Genet2008;40:1461-5 PMCID:PMC2597056

[106] Speliotes EK,Palmer CD.PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease..Hepatology2010;52:904-12 PMCID:PMC3070300

[107] Rotman Y,Zmuda JM,Liang TJ.The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease..Hepatology2010;52:894-903 PMCID:PMC2932770

[108] Valenti L,Daly AK.Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease..Hepatology2010;51:1209-17

[109] Sookoian S.Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease..Hepatology2011;53:1883-94

[110] Liu YL,Leathart JB.Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma..J Hepatol2014;61:75-81

[111] Dubuquoy C,Lasnier F.Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes..J Hepatol2011;55:145-53

[112] Huang Y,Li JZ.A feed-forward loop amplifies nutritional regulation of PNPLA3..Proc Natl Acad Sci U S A2010;107:7892-7 PMCID:PMC2867902

[113] Hao L,Huang KH,Lambert JD.Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells..Metabolism2014;63:1352-62 PMCID:PMC4175036

[114] BasuRay S,Cohen JC.The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation..Hepatology2017;66:1111-24 PMCID:PMC5605398

[115] Nishioji K,Kobayashi M.The impact of PNPLA3 rs738409 genetic polymorphism and weight gain >/=10 kg after age 20 on non-alcoholic fatty liver disease in non-obese japanese individuals..PLoS One2015;10:e0140427 PMCID:PMC4617644

[116] Honda Y,Kessoku T.Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors..Hepatol Res2016;46:1011-8

[117] Leung JC,Wei JL.Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients..Hepatology2017;65:54-64

[118] Fracanzani AL,Lombardi R.Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity..Clin Gastroenterol Hepatol2017;15:1604-11.e1

[119] Younossi ZM.Non-alcoholic fatty liver disease - a global public health perspective..J Hepatol2019;70:531-44

[120] Fan Y,Guo Y.Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice..Gastroenterology2016;150:1208-18 PMCID:PMC4842105

[121] Kozlitina J,Stender S.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease..Nat Genet2014;46:352-6 PMCID:PMC3969786

[122] Liu YL,Burt AD.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease..Nat Commun2014;5:4309 PMCID:PMC4279183

[123] Goffredo M,Feldstein AE.Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: a multiethnic study..Hepatology2016;63:117-25 PMCID:PMC4688225

[124] Chen X,De L,Su S.The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: a meta-analysis of 24,147 subjects..Mol Genet Genomic Med2019;7:e824 PMCID:PMC6687636

[125] Dongiovanni P,Maglio C.Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease..Hepatology2015;61:506-14

[126] Chen F,Rogers GB.Lean NAFLD: a distinct entity shaped by differential metabolic adaptation..Hepatology2020;71:1213-27

[127] Adams LA,Ayonrinde OT.Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity..J Gastroenterol Hepatol2012;27:1520-7

[128] Musso G,Bo S,Gambino R.Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism..Diabetes2013;62:1109-20 PMCID:PMC3609558

[129] Bale G,Mitnala S.Whole-exome sequencing identifies a variant in phosphatidylethanolamine N-methyltransferase gene to be associated with lean-nonalcoholic fatty liver disease..J Clin Exp Hepatol2019;9:561-8 PMCID:PMC6823660

[130] Dong H,Li C.The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population..J Hepatol2007;46:915-20

[131] Song J,Fischer LM.Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD)..FASEB J2005;19:1266-71 PMCID:PMC1256033

[132] Nakatsuka A,Yamaguchi S.Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis..Sci Rep2016;6:21721 PMCID:PMC4756298

[133] Yun Y,Lee EJ.Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects..PLoS One2019;14:e0213692 PMCID:PMC6417675

[134] Machado MV.Diet, microbiota, obesity, and NAFLD: a dangerous quartet..Int J Mol Sci2016;17:481 PMCID:PMC4848937

[135] Ponziani FR,Castelli C.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease..Hepatology2019;69:107-20

[136] Elshaghabee FMF,Meske D.Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions..Front Microbiol2016;7:47 PMCID:PMC4732544

[137] Elshaghabee FMF,Habermann D.Effect of oral administration of weissella confusa on fecal and plasma ethanol concentrations, lipids and glucose metabolism in wistar rats fed high fructose and fat diet..Hepat Med2020;12:93-106 PMCID:PMC7326399

[138] Koutnikova H,Monteiro-Sepulveda M.Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials..BMJ Open2019;9:e017995 PMCID:PMC6475231

[139] Kwak JH,Lee SM.Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: a cross-sectional study..Clin Nutr2018;37:1550-7

[140] Assy N,Kamayse I.Soft drink consumption linked with fatty liver in the absence of traditional risk factors..Can J Gastroenterol2008;22:811-6 PMCID:PMC2661299

[141] Musso G,De Michieli F.Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis..Hepatology2003;37:909-16

[142] Bardella MT,Pagliari C.Searching for coeliac disease in patients with non-alcoholic fatty liver disease..Dig Liver Dis2004;36:333-6

[143] Emami MH,Kouhestani S,Karimi S.Should we look for celiac disease among all patients with liver function test abnormalities?.Int J Prev Med2012;3:167-72 PMCID:PMC3309630

[144] Bakhshipour A,Moulaei N.Prevalence of coeliac disease in patients with non-alcoholic fatty liver disease..Arab J Gastroenterol2013;14:113-5

[145] Rahimi AR,Ghofrani H.The prevalence of celiac disease among patients with non-alcoholic fatty liver disease in Iran..Turk J Gastroenterol2011;22:300-4

[146] Bargiggia S,Elli M.Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center..J Clin Gastroenterol2003;36:417-20

[147] Tovoli F,Fari R.Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors..Aliment Pharmacol Ther2018;48:538-46

[148] Reilly NR,Hultcrantz R,Ludvigsson JF.Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease..J Hepatol2015;62:1405-11 PMCID:PMC4439270

[149] Abenavoli L,De Lorenzo A.A pathogenetic link between non-alcoholic fatty liver disease and celiac disease..Endocrine2013;43:65-7

[150] van Zutphen T,Bloks VW.Malnutrition-associated liver steatosis and ATP depletion is caused by peroxisomal and mitochondrial dysfunction..J Hepatol2016;65:1198-208

[151] Machado MV.Insulin resistance and steatosis in chronic hepatitis C..Ann Hepatol.2009;8 Suppl 1:S67-75

[152] HH AK.Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD)..Expert Rev Gastroenterol Hepatol2017;11:911-24

[153] Reynolds TM,Hamilton J,group PPC.Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy..J Clin Pathol2018;71:608-13

[154] Khoury J,Shehadeh N.Glycogenic hepatopathy..Hepatobiliary Pancreat Dis Int2018;17:113-8

[155] Welty FK.Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease..Curr Opin Lipidol2020;31:49-55

[156] Noto D,Tarugi P,Barbagallo CM.Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature..Acta Diabetol2017;54:111-22

[157] Pelusi S,Pietrelli A.Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease..Sci Rep2019;9:3682 PMCID:PMC6403344

[158] Dela Cruz ACD,George J.Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease: international follow up study..Gastroenterology2014;146:A379

[159] Shao C,Li F,Wang W.Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease..Dig Liver Dis2019;51:1392-9

[160] Hagstrom H,Ekstedt M.Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study..Hepatol Commun2018;2:48-57 PMCID:PMC5776871

[161] Alam S,Alam M,Chowdhury ZR.Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh..Indian J Gastroenterol2014;33:452-7

[162] Denkmayr L,Stechemesser L.Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients..J Clin Med2018;7: PMCID:PMC6306845

[163] Akyuz U,Yilmaz Y.Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels..Scand J Gastroenterol2015;50:341-6

[164] Yilmaz Y,Ayyildiz T.Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome..Eur J Clin Invest2012;42:411-8

[165] Fukuda T,Kojima T.The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals..Liver Int2016;36:275-83

[166] Golabi P,Fukui N,de Avilla L.Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality..Clin Diabetes2019;37:65-72 PMCID:PMC6336127

[167] European Association for the Study of the L, European Association for the Study of D, European Association for the Study of OEASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease..J Hepatol2016;64:1388-402

[168] Alam S,Khan MAS,Hasan N.Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient..J Transl Int Med2019;7:106-14 PMCID:PMC6795050

[169] Albu JB,Kelley DE.Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes..Diabetes2010;59:627-33 PMCID:PMC2828653

[170] Ohkawara K,Miyachi M,Tabata I.A dose-response relation between aerobic exercise and visceral fat reduction: systematic review of clinical trials..Int J Obes (Lond)2007;31:1786-97

[171] Ismail I,Baker MK.A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat..Obes Rev2012;13:68-91